A Lincoln biopharmaceutical company is getting a $20 million venture capital investment to improve vaccines.
Adjuvance Technologies CEO Tyler Martin tells KLIN News the investment helps move projects forward towards a clinical trial.
“This novel human coronavirus virus that’s coming out of China (for example),” Adjuvance Technologies CEO Tyler Martin tells KLIN News. “Whether our adjuvant could be added to that vaccine to make it more effective.”
He says the investment only gets them through a clinical trial, which is about three years. Typically, Martin said it takes $800 million to get a drug through FDA approval.
“Developing new drugs is an expensive business and that’s why the capital needs are so much higher than in other areas,” he says.
Martin’s company develops ‘adjuvants’ things you create to add to vaccines like the flu or coronavirus to improve their strength.
This is one example of how the frontier of new medicine is in our back yard.
Martin tells says University’s Innovation Campus, developing technology and UNMC makes Nebraska a perfect fit.
All these things work together to make this atmosphere that’s conducive to growing companies,” Martin says. “It does take a group of poeole, not just one person, to make something like this work.”
He says this is ground breaking research.